Publications

Export 2668 results:
Sort by: Author [ Title  (Desc)] Type Year
A B C D E F G [H] I J K L M N O P Q R S T U V W X Y Z   [Show ALL]
H
Abulghar, M., A. Nada, O. Azmy, and O. Shawky, "Hysteroscopic Tubal Electrocoagulation In Cases With Communicating Hydrosalpinx And Planning For IVF- A Pilot Study", The International Medical Journal , 2008.
AH, G., "Hysteroscopic resection of type 2 submucous fibroids", The 15th annual conference of the department of obstetrics and gynaecology, Cairo-Egypt, Cairo university-Department of obstetrics and gynaecology, 2014.
Zayed, M., U. M. Fouda, S. M. Zayed, K. A. Elsetohy, and A. T. Hashem, "Hysteroscopic Myomectomy of Large Submucous Myomas in a 1-Step Procedure Using Multiple Slicing Sessions Technique.", J Minim Invasive Gynecol. 2015, vol. 22, issue 7, pp. 1196-202, 2015.
Zayed, M., U. M. Fouda, S. M. Zayed, K. A. Elsetohy, and A. T. Hashem, "Hysteroscopic Myomectomy of Large Submucous Myomas in a 1-Step Procedure Using Multiple Slicing Sessions Technique", Journal of Minimally Invasive Gynecology,, vol. 22, issue 7, pp. 1196-1202, 2015. hysteroscopic_myomectomy_of_large_submucous_myomas_in_a_1-step_procedure_using_multiple_slicing_sessions_technique.pdf
A.L.Aboul-Nasr, H. G. Al-Inany, and S.M.Thabet, "Hysteroscopic metroplasty in recurrent aborters and infertile patients.", Egypt. J. Fertil. Steril. , vol. 4, issue 1, pp. 55-58, 2000.
Shawki, O., A. Wahba, and H. Al-Inany, "Hysteroscopic Management of endometrial bleeding and IUD ", Nezhat's Video assisted and Robotic assisted Laparoscopy and Hysteroscopy, UK, Cambridge University Press , 2013.
A.L.Aboul-Nasr, R.A.Ezzat, A. El-Hennawy, E.Fateen, N. Abdel-Kader, and S.S.Hassan, "Hysteroscopic localization of intrauterine devices in cases with uterine bleeding. ", Med. J. Cairo Univ. , vol. 64, issue 2, pp. 365-376, 1996.
A.L.Aboul-Nasr, S.M.Thabet, H.G.Al-Inany, and M.Aboulghar, "Hysteroscopic evaluation of the uterine cavity following surgical evacuation. ", Middle East Fertil. Soc. J. , vol. 3, issue 2, pp. 137-144, 1998.
A.L.Aboul-Nasr, "Hysteroscopic endometrial ablation. ", Middle East Fertil Soc. J. , vol. 2, issue 3, pp. 185-194, 1997.
Abu‐El‐Rub Ejlal, Sareen Niketa, Lester Sequiera Glen, I. Ammar Hania, Yan Weiang, M. ShamsEldeen Asmaa, Rubinchik Ilan, Moudgil Meenal, S. Shokry Heba, A. Rashed Laila, et al., "Hypoxia‐induced increase in Sug1 leads to poor post‐transplantation survival of allogeneic mesenchymal stem cells", The FASEB Journal, 2020.
Dhingra, S., N. Sareen, Ejlal Abu‐El‐Rub, Hania I. Ammar, Weiang Yan, G. L. Sequiera, Asmaa M. ShamsEldeen, M. Moudgil, Rimpy Dhingra, Heba S. Shokry, et al., "Hypoxia‐induced downregulation of cyclooxygenase 2 leads to the loss of immunoprivilege of allogeneic mesenchymal stem cells", The FASEB Journal, 2020.
Abd ElAziz, A. M., H. S. Abdel Hamid, R. R. Mostafa, and Y. R. A. Shalaby, "Hypoxia-inducible factor-1α expression in colorectal carcinoma", Egypation Journal of Pathology, vol. 38, issue 1, pp. 18–21, 2018.
KANDIL, E. S. R. A. A. A., R. H. Sayed, L. A. Ahmed, M. A. Abd El Fattah, and B. M. El-Sayeh, "Hypoxia-inducible factor 1 alpha and nuclear-related receptor 1 as targets for neuroprotection by albendazole in a rat rotenone model of Parkinson's disease.", Clinical and experimental pharmacology & physiology, vol. 46, issue 12, pp. 1141-1150, 2019. Abstract

Hypoxia-inducible factor-1 alpha (HIF-1α) and nuclear receptor related-1 (Nurr1) play pivotal roles in the development and survival of dopaminergic neurons, and deficiencies in these genes may be involved in Parkinson's disease (PD) pathogenesis. Recently, anthelminthic benzimidazoles were shown to promote HIF-1α transcription in vitro and were proposed to activate Nurr1 via their benzimidazole group. Therefore, the aim of this study was to explore the neuroprotective effects of albendazole (ABZ), an anthelminthic benzimidazole, in a rotenone model of Parkinson's disease (PD). Rotenone (1.5 mg/kg) was subcutaneously injected into rats every other day for a period of 21 days, resulting in the development of the essential features of PD. In addition to rotenone, ABZ (10 mg/kg) was administered orally starting from the 11th day. Treatment of rats with ABZ markedly mitigated rotenone-induced histological alterations in substantia nigra (SN), restored striatal dopamine (DA) level and motor functions and decreased the expression of α-synuclein (a disease marker protein). ABZ also enhanced expression of Hypoxia-inducible factor-1 alpha (HIF-1α) in the SN along with its downstream target, vascular endothelial growth factor, promoting neuronal survival. Similarly, ABZ augmented nuclear receptor related-1 (Nurr1) expression in the SN and increased transcriptional activation of Nurr1-controlled genes, which are essential for regulation of DA synthesis; additionally, expression of neurotoxic proinflammatory cytokines that induce neuronal death was suppressed. In conclusion, the present study suggests that ABZ exerts a neuroprotective effect in a rotenone-induced PD model associated with HIF-1α and Nurr1 activation and thus may be a viable candidate for treating PD.

KANDIL, E. S. R. A. A. A., R. H. Sayed, L. A. Ahmed, M. A. Abd El Fattah, and B. M. El-Sayeh, "Hypoxia-inducible factor 1 alpha and nuclear-related receptor 1 as targets for neuroprotection by albendazole in a rat rotenone model of Parkinson's disease.", Clinical and experimental pharmacology & physiology, vol. 46, issue 12, pp. 1141-1150, 2019. Abstract

Hypoxia-inducible factor-1 alpha (HIF-1α) and nuclear receptor related-1 (Nurr1) play pivotal roles in the development and survival of dopaminergic neurons, and deficiencies in these genes may be involved in Parkinson's disease (PD) pathogenesis. Recently, anthelminthic benzimidazoles were shown to promote HIF-1α transcription in vitro and were proposed to activate Nurr1 via their benzimidazole group. Therefore, the aim of this study was to explore the neuroprotective effects of albendazole (ABZ), an anthelminthic benzimidazole, in a rotenone model of Parkinson's disease (PD). Rotenone (1.5 mg/kg) was subcutaneously injected into rats every other day for a period of 21 days, resulting in the development of the essential features of PD. In addition to rotenone, ABZ (10 mg/kg) was administered orally starting from the 11th day. Treatment of rats with ABZ markedly mitigated rotenone-induced histological alterations in substantia nigra (SN), restored striatal dopamine (DA) level and motor functions and decreased the expression of α-synuclein (a disease marker protein). ABZ also enhanced expression of Hypoxia-inducible factor-1 alpha (HIF-1α) in the SN along with its downstream target, vascular endothelial growth factor, promoting neuronal survival. Similarly, ABZ augmented nuclear receptor related-1 (Nurr1) expression in the SN and increased transcriptional activation of Nurr1-controlled genes, which are essential for regulation of DA synthesis; additionally, expression of neurotoxic proinflammatory cytokines that induce neuronal death was suppressed. In conclusion, the present study suggests that ABZ exerts a neuroprotective effect in a rotenone-induced PD model associated with HIF-1α and Nurr1 activation and thus may be a viable candidate for treating PD.

AbdelMassih, A., E. Yacoub, R. J. Husseiny, A. Kamel, R. Hozaien, M. El Shershaby, M. Rajab, S. Yacoub, M. A. Eid, M. Elahmady, et al., "Hypoxia-inducible factor (HIF): The link between obesity and COVID-19.", Obesity medicine, vol. 22, pp. 100317, 2021. Abstract

The COVID-19 death toll has involved to date more than 1 million confirmed deaths. The death rate is even higher in the obese COVID-19 patients, as a result of hypoxia, due to the interplay between adipose tissue hypoxia and obstructive sleep apnea. The discrepancy of manifestations seen in COVID-19 seems to be mediated by a differential immune response rather than a differential viral load. One of the key players of the immune response is HIF. HIF-1β is a stable constitutively expressed protein in the nucleus; and under hypoxic changes, its activity is unaffected, whereas the HIF-α subunit has a short half-life and because of its degradation by an enzyme known as propyl hydroxylase; under hypoxic conditions, propyl hydroxylase gets deactivated thus leading to the stabilization of HIF-1α. As mentioned before, HIF-1α expression is triggered by hypoxic states, this crippling condition will aggravate the pro-inflammatory characteristics of HIF-1α. The vast majority of decompensated COVID19 cases manifest with drastic lung injury and severe viral pneumonia, the infection-induced hypoxia will the existing hypoxia in obesity. This will additionally augment HIF-1α levels that will provoke the already existing cytokines' storm to fulminant. Consequently, this will directly correlate the effect of a hypoxic environment with the increase of HIF-1α level. HIFɑ exists in two main isoforms HIF-1α and HIF-2α. HIF-1α and HIF-2α act in distinct ways in how they work on different target genes. For example, HIF-2α may act on hemopoietin genes (heme-regulating genes); while HIF-1α acts on EPO. HIF-1α release seems to be markedly augmented in obesity due to adipose tissue hypoxia and obstructive sleep apnea resulting in cyclic hypoxia. HIF-1α can also be secreted by direct viral proteolytic effects. Whereas, HIF-2α is stimulated by chronic hypoxia. HIF-1α exerts detrimental effects on the immune system, characterized by unopposed pro-inflammation at the macrophages, dendritic cells, T cells, and complement levels resulting in cytokines' storm, which is linked to the poor outcomes of COVID-19. On the other hand, HIF-2α role is regulatory and largely opposes the actions mediated by HIF-1α. In view of this, inhibiting HIF-1α release or switching its production to HIF-2α by natural products such as resveratrol or by synthetic drugs, offer a good therapeutic strategy that can prevent COVID-19 worst outcome in infected patients. The approach of breaking the vicious circle between lung damage-induced hypoxia and HIF-1α pro-inflammatory stimulant through drugs is considered to be extremely promising as a therapeutic manner to combat further deterioration of COVID19 cases.

Zamzam, S. M., H. M. Abdelkader, G. Subedi, and O. A. Alhossainy, "Hypovitaminosis D and its relationship to nasal polyposis", Pan Arab Journal of Rhinology, 2022.
MASHALY, M. A. G. D. I. M., S. A. N. D. R. A. L. YOUTZ, and R. F. Wideman, "Hypothyroidism and Antibody Prodction in Immature Male Chickens", Immunological Investigations, vol. 12, issue 6: Informa UK Ltd UK, pp. 551-563, 1983. Abstract
n/a
K.M., M., S. F.K., S. S.S., S. K.F., and K. M.G., "Hypothermic effect of ethanol in mice selected for differential sleep-time response to pentobarbital.", Pharmacol Biochem Behav., vol. 51, issue 2-3, pp. 525-8., 1995. Abstract
n/a
Mohammed, H. S., "Hypothermia mitigates neurochemical alterations in rat's cerebral cortex during status epilepticus induced by pilocarpine.", General Physiology and Biophysics, vol. 34, no. 4, pp. 425–432, 2015. Abstract
n/a
El-Darouti, M. A., M. M. Fawzy, R. A. HEGAZY, and R. M. Abdel Hay, "Hypopigmented parapsoriasis en plaque, a new, overlooked member of the parapsoriasis family: a report of 34 patients and a 7-year experience.", Journal of the American Academy of Dermatology, vol. 67, issue 6, pp. 1182-8, 2012 Dec. Abstract

BACKGROUND: In the past 7 years we have extensively studied an uncommon hypopigmented disorder that, apart from hypopigmentation, showed many common features with parapsoriasis en plaque (PSEP), both clinically and histopathologically.

OBJECTIVE: We sought to verify whether this disorder should be considered a hypopigmented variant of PSEP and thus be referred to as hypopigmented PSEP.

METHODS: A total of 34 patients presenting with this peculiar hypopigmented disorder were included (2003-2010). Patients were subjected to a predesigned algorithm excluding all possible differential diagnoses of hypopigmented lesions.

RESULTS: Our findings indicated that this disorder can be diagnosed as hypopigmented PSEP. These findings included: (1) exclusion of all other disorders causing similar hypopigmented lesions; (2) shape and size of the lesions being very similar to those of classic small PSEP (small-plaque parapsoriasis [SPP]); (3) similar distribution of the lesions (trunk, proximal upper and lower limbs) to the classic PSEP; (4) digitiform extensions of most the lesions (70.5% of our patients) as in SPP; (5) absence of itching as in PSEP (SPP type); (6) good response to narrowband ultraviolet B in 76.4% of the patients (n = 26); and (7) during follow-up 5 patients (14.7%) converted into hypopigmentd mycosis fungoides.

LIMITATIONS: A limitation in our study is that we did not perform clonal T-cell receptor gene rearrangement because of limited resources.

CONCLUSION: Based on our findings we believe that this hypopigmented disorder is a well-defined new variant of the PSEP family that shows, apart from the hypopigmentation, all the features of PSEP, particularly the SPP variant, and accordingly could be referred to as hypopigmented PSEP.

El-Darouti, M. A., M. M. Fawzy, R. A. HEGAZY, and R. M. Abdel Hay, "Hypopigmented parapsoriasis en plaque, a new, overlooked member of the parapsoriasis family: A report of 34 patients and a 7-year experience", Journal of the American Academy of Dermatology, vol. 67, no. 6: Elsevier, pp. 1182–1188, 2012. Abstract
n/a
El-Darouti, M. A., M. M. Fawzy, R. A. HEGAZY, and R. A. M. Hay, "Hypopigmented parapsoriasis en plaque, a new, overlooked member of the parapsoriasis family: a report of 34 patients and a 7-year experience", Journal of the American Academy of Dermatology, vol. 67, no. 6: Mosby, pp. 1182–1188, 2012. Abstract
n/a
Tourism